Pharmacogenetics and psychopharmacotherapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 3, 2000, Pages 197-220

  Poolsup, ^a   Po, Li Wan ^a   Knight, ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 2C19; DIAZEPAM; HEXOBARBITAL; IMIPRAMINE; NEUROLEPTIC AGENT; OMEPRAZOLE; PROPRANOLOL;

ASIAN; CAUCASIAN; CULTURAL FACTOR; DNA POLYMORPHISM; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 0033929925     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00281.x     Document Type: Review

References (164)

1. 1 Rowland M. (1994) Concern for individual. Journal of Pharmacy and Pharmacology, 46 (Suppl. 1), 405 407.
2. 2 Tam YK. (1993) Individual variation in first‐pass metabolism. Clinical Pharmacokinetics, 25, 300 328.
3. 3 Van den Anker JN. (1996) Pharmacokinetics and renal functions in preterm infants. Acta Paediatrica, 85, 1393 1399.
4. 4 Sowinski KM, Abel SR, Clark WR, et al. ( 1999) Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy, 19, 442 446.
5. 5 Harris RZ, Benet LZ, Schwartz JB. (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs, 50, 222 239.
6. 6 Matthews HW. (1995) Racial, ethnic and gender differences in response to medicines. Drug Metabolism and Drug Interactions, 12, 77 91.
7. 7 Kloner RA, Sowers JR, DiBona GF, et al. ( 1996) Sex‐ and age‐related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. American Journal of Cardiology, 77, 713 722.
8. 8 Morgan DJ & McLean AJ. (1995) Clinical pharmacokinetic and pharmacodynamics considerations in patients with liver disease. An update. Clinical Pharmacokinetics, 29, 370 391.
9. 9 Souich R, Verges J, Erill S. (1993) Plasma protein binding and pharmacological response. Clinical Pharmacokinetics, 24, 435 440.
10. 10 Meyer UA. (1994) The molecular basis of genetic polymorphisms of drug metabolism. Journal of Pharmacy and Pharmacology, 46 (Suppl. 1), 409 415.
11. 11 Eichelbaum M & Evert B. (1996) Influence of pharmacogenetics on drug disposition and response. Clinical and Experimental Pharmacology and Physiology, 23, 983 985.
12. 12 Eichelbaum M. (1982) Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics, 7, 1 22.
13. 13 Kalow W. (1993) Pharmacogenetics: its biological roots and the medical challenge. Clinical Pharmacology and Therapeutics, 54, 235 241.
14. 14 Meyer UA, Zanger UM, Grant D, et al. ( 1990) Genetic polymorphisms of drug metabolism. Advances in Drug Research, 19, 197 241.
15. 15 Kalow W. (1991) Interethnic variation of drug metabolism. Trends in Pharmacological Sciences, 12, 102 107.
16. 16 Vesell ES. (1984) New directions in pharmacogenetics: introduction. Federal Proceedings, 43, 2319 2325.
17. 17 Kalow W. (1994) Pharmacogenetic variability in brain and muscle. Journal of Pharmacy and Pharmacology, 46 (Suppl. 1), 425 432.
18. 18 Kalow W. (1984) Pharmacoanthropology: drug metabolism. Federal Proceedings, 43, 2326 2331.
19. 19 Lin KM, Poland RE, Wan YY, et al. ( 1996) The evolving science pharmacogenetics: clinical and ethnic perspectives. Psychopharmacology Bulletin, 32, 205 217.
20. 20 Hughes HB, Biehl JP, Jones AP, et al. ( 1954) Metabolism of isoniazid in man as related to the occurrence of peripheral isoniazid neuritis. American Review of Tuberculosis, 70, 266 273.
21. 21 Wood AJJ & Zhou HH. (1991) Ethnic differences in drug disposition and responsiveness. Clinical Pharmacokinetics, 20, 350 373.
22. 22 Kalow W. (1990) Pharmacogenetics: past and future. Life Sciences, 47, 1385 1397.
23. 23 Levy RA. (1993) Ethnic and racial differences in response to medicines: preserving individualized therapy in managed pharmaceutical programmes. Pharmaceutical Medicine, 7, 139 165.
24. 24 Lin KM & Poland RE. (1995) Ethnicity, culture, and psychopharmacology. In: Kupfer DJ, Bloom FE, eds. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press, 1907–1917.
25. 25 Smith SE & Rawlins MD. (1976) Variability in Human Drug Response. London: Butterworths.
26. 26 Inaba T, Nebert DW, Burchell B, et al. ( 1995) Pharmacogenetics in clinical pharmacology and toxicology. Canadian Journal of Physiology and Pharmacology, 73, 331 338.
27. 27 Arias TD, Jorge LF, Barrantes R. (1991) Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics. British Journal of Clinical Pharmacology, 31, 117 118.
28. 28 Gonzalez FJ & Idle JR. (1994) Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clinical Pharmacokinetics, 26, 59 70.
29. 29 Parkinson A. (1996) Biotransformation of xenobiotics. In: Klaassen CD, ed. Casarett and Doull’s Toxicology. The Basic Science of Poisons. 5th edn. New York: McGraw‐Hill, 113–186.
30. 30 Blaauboer BM. (1996) Biotransformation: detoxication and bioactivation. In: Niesink RJM, de Vries J, Hollinger MA, eds. Toxicology Principles and Applications. Boca Raton: CRC Press, 40–65.
31. 31 Spatzenegger M & Jaeger W. (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews, 27, 397 417.
32. 32 Slaughter RL & Edwards DJ. (1995) Recent advances: the cytochrome P450 enzymes. Annals of Pharmacotherapy, 29, 619 624.
33. 33 Tanaka E. (1998) Clinical important pharmacokinetics drug–drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23, 403 416.
34. 34 Nebert DW & McKinnon RA. (1994) Cytochrome P450: evolution and functional diversity. Progress in Liver Diseases, 12, 63 97.
35. 35 Ingelman‐Sundberg M, Oscarson M, McLellan RA. (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualised drug treatment. Trends in Pharmacological Sciences, 20, 342 349.
36. 36 Bertilsson L. (1995) Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics, 29, 192 209.
37. 37 Smith MW & Mendoza RP. (1996) Ethnicity and pharmacogenetics. Mount Sinai Journal of Medicine, 63, 285 290.
38. 38 Meyer UA. (1994) Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proceedings of the National Academy of Sciences of the USA, 91, 1983 1984.
39. 39 Brosen K & Gram LF. (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 36, 537 547.
40. 40 Kalow W & Bertilsson L. (1994) Interethnic factors affecting drug response. Advances in Drug Research, 25, 1 53.
41. 41 Guttendorf RJ & Wedlund PJ. (1992) Genetic aspects of drug disposition and therapeutics. Journal of Clinical Pharmacology, 32, 107 117.
42. 42 Relling MV, Cherrie J, Schell MJ, et al. ( 1991) Lower prevalence of the debrisoquine oxidative poor metaboliser phenotype in American black versus white subjects. Clinical Pharmacology and Therapeutics, 50, 308 313.
43. 43 Wedlund PJ, Aslanian WS, McAllister CB, et al. ( 1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clinical Pharmacology and Therapeutics, 36, 773 780.
44. 44 Peart GF, Boutagy J, Shenfield GM. (1986) Debrisoquine oxidation in an Australian population. British Journal of Clinical Pharmacology, 21, 465 471.
45. 45 Leclercq V, Desager JP, Nieuwenhuyze YV, et al. ( 1987) Prevalence of drug hydroxylator phenotypes in Belgium. European Journal of Clinical Pharmacology, 33, 439 440.
46. 46 Evans DA, Mahgoub A, Sloan TP, et al. ( 1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics, 17, 102 105.
47. 47 Vinks A, Inaba T, Otton SV, et al. ( 1982) Sparteine metabolism in Canadian Caucasians. Clinical Pharmacology and Therapeutics, 31, 23 29.
48. 48 Inaba T, Jurima M, Nakano M, et al. ( 1984) Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clinical Pharmacology and Therapeutics, 36, 670 676.
49. 49 Lou YC, Ying L, Bertilsson L, et al. ( 1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet, 2, 852 852.
50. 50 Sohn DR, Shin SG, Park CW, et al. ( 1991) Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. British Journal of Clinical Pharmacology, 32, 504 507.
51. 51 Bertilsson L, Lou YQ, Yun‐Long D, et al. ( 1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S‐mephenytoin. Clinical Pharmacology and Therapeutics, 51, 388 397.
52. 52 Lee EJ, Nam YP, Hee GN. (1988) Oxidation phenotyping in Chinese and Malay populations. Clinical and Experimental Pharmacology and Physiology, 15, 889 891.
53. 53 Arias TD, Jorge LF, Lee D, et al. ( 1988) The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolisers. Clinical Pharmacology and Therapeutics, 43, 456 465.
54. 54 Brosen K, Otton SV, Gram LF. (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacologica et Toxicologica (Copenhagen), 57, 357 360.
55. 55 Drohse A, Bathum L, Brogen K, et al. ( 1989) Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. British Journal of Clinical Pharmacology, 27, 620 625.
56. 56 Tamminga WJ, Wemer J, Oosterhuis B, et al. ( 1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indication for oral contraceptive‐related gender differences. European Journal of Clinical Pharmacology, 55, 177 184.
57. 57 Mahgoub A, Idle JR, Smith RL. (1979) A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica, 9, 51 56.
58. 58 Kiivet RA, Svensson JO, Bertilsson L, et al. ( 1993) Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. Pharmacology and Toxicology, 72, 113 115.
59. 59 Marandi T, Dahl ML, Kiivet RA, et al. ( 1996) Debrisoquine and S‐mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacology and Toxicology, 78, 303 307.
60. 60 Aklillu E, Persson I, Bertilsson L, et al. ( 1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Journal of Pharmacology and Experimental Therapeutics, 278, 441 446.
61. 61 Evans DA, Krahn P, Narayanan N. (1995) The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics, 5, 64 71.
62. 62 Larrey D, Amouyal G, Tinel M, et al. ( 1987) Polymorphism of dextromethorphan oxidation in a French population. British Journal of Clinical Pharmacology, 24, 676 679.
63. 63 Vincent‐Viry MV, Fournier B, Siest G, et al. ( 1992) Dextromethorphan O‐demethylation in a alrge number of French Caucasian families. Pharmacogenetics, 2, 135 138.
64. 64 Jacqz E, Dulac H, Mathieu H. (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. European Journal of Clinical Pharmacology, 35, 167 171.
65. 65 Ishizaki T, Eichelbaum M, Horia Y, et al. ( 1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. British Journal of Clinical Pharmacology, 23, 482 485.
66. 66 Woolhouse NM, Andoh B, Mahgoub A, et al. ( 1979) Debrisoquine hydroxylation polymorphism among Ghanaians and Caucasians. Clinical Pharmacology and Therapeutics, 26, 584 591.
67. 67 Griese EU, Asante‐Poku S, Ofori‐Adjei D, et al. ( 1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics, 9, 715 723.
68. 68 Eichelbaum M & Woolhouse NM. (1985) Inter‐ethnic difference in sparteine oxidation among Ghanaians and Germans. European Journal of Clinical Pharmacology, 28, 79 83.
69. 69 Brosen K. (1986) Sparteine oxidation polymorphism in Greenlanders living in Denmark. British Journal of Clinical Pharmacology, 22, 415 419.
70. 70 Clasen K, Madsen L, Brosen K, et al. ( 1991) Sparteine and mephenytoin oxidation. Genetic polymorphism in East and West Greenland. Clinical Pharmacology and Therapeutics, 49, 624 631.
71. 71 Setiabudy R, Kusaka M, Chiba K, et al. ( 1994) Dapsone N‐acetylation, metoprolol alpha‐hydroxylation, and S‐mephenytoin 4‐hydroxylation polymorphism in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clinical Pharmacology and Therapeutics, 56, 142 153.
72. 72 Spina E, Campo GM, Avenoso A, et al. ( 1994) CYP2D6‐related oxidation polymorphism in Italy. Pharmacological Research, 29, 281 289.
73. 73 Nakamura K, Goto F, Ray WA, et al. ( 1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics, 10, 402 408.
74. 74 Hadidi HF, Cholerton S, Monkman SC, et al. ( 1994) Debrisoquine 4‐hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics, 4, 159 161.
75. 75 Roh HK, Dahl ML, Johansson I, et al. ( 1996) Debrisoquine and S‐mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 6, 441 447.
76. 76 Wanwimolruk S, Pratt EL, Denton JR, et al. ( 1995) Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics, 5, 193 198.
77. 77 Wanwimolruk S, Denton JR, Ferry DG, et al. ( 1992) Polymorphism of debrisoquine oxidation in New Zealand Caucasians. European Journal of Clinical Pharmacology, 42, 349 350.
78. 78 Mbanefo C, Bababunmi EA, Mahgoub A, et al. ( 1980) A study of debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica, 10, 811 818.
79. 79 Kunicki PK, Sitkiewicz D, Pawlik A, et al. ( 1995) Debrisoquine hydroxylation in a Polish population. European Journal of Clinical Pharmacology, 47, 503 505.
80. 80 Marandi T, Dahl ML, Rago L, et al. ( 1997) Debrisoquine and S‐mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. European Journal of Clinical Pharmacology, 53, 257 260.
81. 81 Sommers DK, Monerieff J, Avenant J. (1988) Polymorphism of the 4‐hydroxylation of debrisoquine in the San Bushmen of Southern Africa. Human Toxicology, 7, 273 276.
82. 82 Islam SI, Idle JR, Smith RL. (1980) The polymorphic 4‐hydroxylation of debrisoquine in a Saudi‐Arab population. Xenobiotica, 10, 819 825.
83. 83 Weerasuriya K, Jayakody RL, Smith AD, et al. ( 1994) Debrisoqiune and mephenytoin oxidation in Sinhalese: a population study. British Journal of Clinical Pharmacology, 38, 466 470.
84. 84 Wanwimolruk S, Bhawan S, Coville PF, et al. ( 1998) Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. European Journal of Clinical Pharmacology, 54, 431 435.
85. 85 Benitez J, Llerena A, Cobaleda J. (1988) Debrisoquine oxidation polymorphism in a Spanish population. Clinical Pharmacology and Therapeutics, 44, 74 77.
86. 86 Steiner E, Bertilsson L, Sawe J, et al. ( 1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clinical Pharmacology and Therapeutics, 44, 431 435.
87. 87 Sanz EJ, Villen T, Alm C, et al. ( 1989) S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clinical Pharmacology and Therapeutics, 45, 495 499.
88. 88 Küpfer A & Preisig R. (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology, 26, 753 759.
89. 89 Bathum L, Skjelbo E, Mutabingwa TK, et al. ( 1999) Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. British Journal of Clinical Pharmacology, 48, 395 401.
90. 90 Wennerholm A, Johansson I, Massele AY, et al. ( 1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9, 707 714.
91. 91 Wanwimolruk S, Patamasucon P, Lee EJD. (1990) Evidence for the polymorphic oxidation of debrisoquine in the Thai population. British Journal of Clinical Pharmacology, 29, 244 247.
92. 92 Bozkurt A, Basci N, Isimer A, et al. ( 1994) Polymorphic debrisoquine metabolism in a Turkish population. Clinical Pharmacology and Therapeutics, 55, 399 401.
93. 93 Lou YC. (1990) Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metabolism Reviews, 22, 451 475.
94. 94 Daniel HI & Edeki TI. (1996) Genetic polymorphism of S‐mephenytoin 4′‐hydroxylation. Psychopharmacology Bullentin, 32, 219 230.
95. 95 Pollock BG, Perel JM, Kirshner M, et al. ( 1991) S‐mephenytoin 4‐hydroxylation in older Americans. European Journal of Clinical Pharmacology, 40, 609 611.
96. 96 Jurima M, Inaba T, Kadar D, et al. ( 1985) Genetic polymorphism of mephenytoin, p(4′)‐hydroxylation: difference between Orientals and Caucasians. British Journal of Clinical Pharmacology, 19, 483 487.
97. 97 Horai Y, Nakano M, Ishizaki T, et al. ( 1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects. Japanese versus mainland Chinese. Clinical Pharmacology and Therapeutics, 46, 198 207.
98. 98 Doshi BS, Kulkarni RD, Chauhan BL, et al. ( 1990) Frequency of impaired mephenytoin 4′‐hydroxylation in an Indian population. British Journal of Clinical Pharmacology, 30, 779 780.
99. 99 Jurima RM, Goldstein JA, LeBelle M, et al. ( 1996) CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics, 6, 329 339.
100. 100 Hadidi HF, Irshaid YM, Woosley RL, et al. ( 1995) S‐mephenytoin hydroxylation phenotypes in a Jordanian population. Clinical Pharmacology and Therapeutics, 58, 542 547.
101. 101 Sohn DR, Kusaka M, Ishizaki T, et al. ( 1992) Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clinical Pharmacology and Therapeutics, 52, 160 169.
102. 102 Reviriego J, Bertilsson L, Carrillo JA, et al. ( 1993) Frequency of S‐mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. European Journal of Clinical Pharmacology, 44, 593 595.
103. 103 Masimirembwa C, Bertilsson L, Johansson I, et al. ( 1995) Phenotyping and genotyping of S‐mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clinical Pharmacology and Therapeutics, 57, 656 661.
104. 104 Cohen LJ & De Vane CL. (1996) Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Annals of Pharmacotherapy, 30, 1471 1480.
105. 105 Allen JJ, Rack PH, Vaddadi KS. (1977) Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgraduate Medical Journ, 53 (Suppl. 4), 79 86.
106. 106 Lewis P, Rack PH, Vadadi KS, et al. ( 1980) Ethnic differences in drug response. Postgraduate Medical Journ, 56 (Suppl. 1), 46 49.
107. 107 Rudorfer MV, Lane EA, Chang WH, et al. ( 1984) Desipramine pharmacokinetics in Chinese and Caucasian volunteers. British Journal of Clinical Pharmacology, 17, 433 440.
108. 108 Pi EH, Simpson GH, Cooper TB. (1986) Pharmacokinetics of desipramine in Caucasian and Asian volunteers. American Journal of Psychiatry, 143, 1174 1176.
109. 109 Pi EH, Tran‐Johnson TK, Walker NR, et al. ( 1989) Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacology Bulletin, 25, 483 487.
110. 110 Kishimoto A & Hollister LE. (1984) Nortriptyline kinetics in Japanese and Americans. Journal of Clinical Psychopharmacology, 4, 171 172.
111. 111 Schneider L, Pawluczyk S, Dopheide J, et al. ( 1991) Ethnic difference in nortriptyline metabolism. New Research Program and Abstract. Washington DC: American Psychiatric Association, 206 206.
112. 112 Gaviria M, Gil AA, Javaid JI. (1986) Nortriptyline kinetics in Hispanic and Anglo subjects. Journal of Clinical Psychopharmacology, 6, 227 231.
113. 113 Ziegler VE & Biggs JT. (1977) Tricyclic plasma levels‐effects of age, race, sex, and smoking. Journal of American Medical Association, 238, 2167 2169.
114. 114 Yamamoto J, Fung D, Lo S, et al. ( 1979) Psychopharmacology for Asian Americans and Pacific Islanders. Psychopharmacology Bulletin, 15, 29 31.
115. 115 Lin KM & Finder E. (1983) Neuroleptic dosage for Asians. American Journal of Psychiatry, 140, 490 491.
116. 116 Lin KM, Poland RE, Nuccio I, et al. ( 1989) A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. American Journal of Psychiatry, 146, 1307 1311.
117. 117 Potkin SG, Shen Y, Pardes H, et al. ( 1984) Haloperidol concentrations elevated in Chinese patients. Psychiatry Research, 12, 167 172.
118. 118 Jann MW, Chang WH, Davis CM, et al. ( 1989) Haloperidol and reduced haloperidol plasma levels in Chinese vs. non‐Chinese psychiatric patients. Psychiatry Research, 30, 45 52.
119. 119 Jann MW, Chang WH, Lam YWF, et al. ( 1992) Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 16, 193 202.
120. 120 Chang WH, Lam YWF, Jann MW, et al. ( 1992) Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology, 106, 517 522.
121. 121 Holley FO, Magliozzi JR, Stanski DR, et al. ( 1983) Haloperidol kinetics after oral and intravenous doses. Clinical Pharmacology and Therapeutics, 33, 477 484.
122. 122 Lin KM, Poland RE, Lau JK, et al. ( 1988) Haloperidol and prolactin concentrations in Asians and Caucasians. Journal of Clinical Psychopharmacology, 8, 195 201.
123. 123 Jann MW, Lam YWF, Chang WH. (1993) Haloperidol and reduced haloperidol plasma concentrations in different ethnic populations and interindividual variabilities in haloperidol metabolism. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington DC: American Psychiatric Press, 133–152.
124. 124 Matsuda KT, Cho MC, Lin KM, et al. ( 1996) Clozapine dosage, serum levels, efficacy, and side‐effect profiles: a comparison of Korean‐American and Caucasian patients. Psychopharmacology Bulletin, 32, 253 257.
125. 125 Chang WH, Lin SK, Lane HY, et al. ( 1997) Clozapine dosages and plasma drug concentrations. Journal of Formosa Medical Association, 96, 599 605.
126. 126 Masimirembwa CM & Hasler JA. (1997) Genetic polymorphism of drug metabolising enzymes in African populations: implication for the use of neuroleptics and antidepressants. Brain Research Bulletin, 44, 561 571.
127. 127 Midha KK, Hawes EM, Hubbard JW, et al. ( 1988) A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology, 95, 333 338.
128. 128 Midha KK, Hawes EM, Hubbard JW, et al. ( 1988) Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology, 96, 206 211.
129. 129 Ghoneim MM, Korttila K, Chiang C‐K, et al. ( 1981) Diazepam effects and kinetics in Caucasians and Orientals. Clinical Pharmacology and Therapeutics, 29, 749 756.
130. 130 Kumana CR, Lauder IJ, Chan M, et al. ( 1987) Differences in diazepam pharmacokinetics in Chinese and White Caucasians – relation to body lipid stores. European Journal of Clinical Pharmacology, 32, 211 215.
131. 131 Lin KM, Poland RE, Silver B. (1993) Overview: the interface between psychobiology and ethnicity. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington DC: American Psychiatric Press, 11–35.
132. 132 Rosenblat R & Tang SW. (1987) Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with Occidentals. Canadian Journal of Psychiatry, 32, 270 274.
133. 133 Collazo J, Tam R, Sramek JJ, et al. ( 1996) Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mount Sinai Journal of Medicine, 63, 310 313.
134. 134 Sramek JJ, Sayles MA, Simpson GM. (1986) Neuroleptic dosage for Asians: a failure to replicate. American Journal of Psychiatry, 143, 535 536.
135. 135 Zhang‐Wong J, Beiser M, Zipursky RB, et al. ( 1998) An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Research, 81, 333 339.
136. 136 Pearlman T. (1984) Different doses of neuroleptics for genetically different groups. American Journal of Psychiatry, 141, 156 157.
137. 137 Strickland TL, Ranganath V, Lin KM, et al. ( 1991) Psychopharmacologic considerations in the treatment of Black American populations. Psychopharmacology Bulletin, 27, 441 448.
138. 138 Adams GL, Dworkin RJ, Rosenberg SD. (1984) Diagnosis and pharmacotherapy issues in the care of Hispanics in the public sector. American Journal of Psychiatry, 141, 970 974.
139. 139 Sramek JJ, Roy S, Ahrens T, et al. ( 1991) Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hospital and Community Psychiatry, 42, 590 592.
140. 140 Frackiewicz EJ, Sramek JJ, Herrara JM, et al. ( 1997) Ethinicity and antipsychotic response. Annals of Pharmacotherapy, 31, 1360 1369.
141. 141 Van Tol HH, Wu CM, Guan HC, et al. ( 1992) Multiple dopamine D4 receptor variants in the human population. Nature, 358, 149 152.
142. 142 Rao PA, Pickar D, Gejman PV, et al. ( 1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Archives of General Psychiatry, 51, 912 917.
143. 143 Rietschel M, Naber D, Oberlander H, et al. ( 1996) Efficacy and side effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology, 15, 491 496.
144. 144 Lieberman JA, Yunis J, Egea E, et al. ( 1990) HLA‐B38, DR4, DQw3 and clozapine‐induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry, 47, 945 948.
145. 145 Binder RL & Levy R. (1981) Extrapyramidal reactions in Asians. American Journal of Psychiatry, 138, 1243 1244.
146. 146 Glazer WM, Morgenstern H, Doucette J. (1994) Race and tardive dyskinesia among outpatients at a CMHC. Hospital and Community Psychiatry, 45, 38 42.
147. 147 Pi EH, Gutierrez MA, Gray GE. (1993) Tardive dyskinesia: cross‐cultural perspectives. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity Washington, DC: American Psychiatric Press, 153–167.
148. 148 Silver B, Poland RE, Lin KM. (1993) Ethnicity and the pharmacology of tricyclic antidepressants. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: American Psychiatric Press, 61–89.
149. 149 Sramek JJ & Pi EH. (1996) Ethnicity and antidepressant response. Mount Sinai Journal of Medicine, 63, 320 325.
150. 150 Kinzie JD & Manson S. (1983) Five years’experience with Indochinese refugee psychiatric patients. Journal of Operational Psychiatry, 14, 13 19.
151. 151 Yamashita I & Asano Y. (1979) Tricyclic antidepressants: therapeutic plasma level. Psychopharmacology Bulletin, 15, 40 41.
152. 152 Hu WH, Lee CF, Yang YY, et al. ( 1983) Imipramine plasma levels and clinical response. Bulletin of Chinese Society of Neurology and Psychiatry, 9, 40 49.
153. 153 Glassman AH, Perel JM, Shostak M, et al. ( 1977) Clinical implications of imipramine plasma levels for depressive illness. Archives of General Psychiatry, 34, 197 204.
154. 154 Lin KM, Poland RE, Smith MW, et al. ( 1991) Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacology Bulletin, 27, 427 439.
155. 155 Escobar JI & Tuason VB. (1980) Antidepressant agents: a cross‐cultural study. Psychopharmacology Bulletin, 16, 49 52.
156. 156 Lawson WB. (1986) Racial and ethnic factors in psychiatry research. Hospital Community Psychiatry, 37, 50 54.
157. 157 Marcos LR & Cancro R. (1982) Pharmacotherapy of Hispanic depressed patients: clinical observations. American Journal of Psychotherapy, 36, 505 513.
158. 158 Pi EH. (1998) Transcultural psychopharmacology: present and future. Psychiatry and Clinical Neurosciences, 52 (Suppl.), S185 S187.
159. 159 Edeki T. (1996) Clinical importance of genetic polymorphism of drug oxidation. Mt Sinai Journal of Medicine, 63, 291 300.
160. 160 Otton SV, Wu D, Joffe RT, et al. ( 1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clinical Pharmacology and Therapeutics, 53, 401 409.
161. 161 Tucker GT. (1994) Clinical implications of genetic polymorphism in drug metabolism. Journal of Pharmacy and Pharmacology, 46 (Suppl. 1), 417 424.
162. 162 Chen S, Chou W, Blouin RA, et al. ( 1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clinical Pharmacology and Therapeutics, 60, 522 534.
163. 163 Zuhlsdorf MT. (1998) Relevance of pheno‐ and genotyping in clinical drug development. International Journal of Clinical Pharmacology and Therapeutics, 36, 607 612.
164. 164 Lichter JB & Kurth JH. (1997) The impact of pharmacogenetics on the future of healthcare. Current Opinion in Biotechnology, 8, 692 695.